Chemotherapy for metastatic breast cancer.

作者: Erica L. Mayer , Harold J. Burstein

DOI: 10.1016/J.HOC.2007.03.001

关键词:

摘要: Cytotoxic chemotherapy is a mainstay of treatment for advanced breast cancer. Treatment metastatic (also called stage IV, advanced, or recurrent) cancer not considered curative. Rather, the goals with are to prolong survival, alleviate prevent tumor-related symptoms complications, and improve quality life. While purpose symptoms, paradoxically carries considerable toxicities that cause substantial in patients, notoriously including fatigue, nausea, vomiting, diarrhea, hair loss, mucositis, neutropenia, neuropathy. Balancing benefits side effects further complicated by natural history cancer, which can be quite prolonged typically involves multiple lines chemotherapy, especially patients whose tumors respond treatment.

参考文章(66)
F Crippa, C Brambilla, F Villani, G Bonadonna, A Rossi, V Bonfante, L Ferrari, Phase II study of doxorubicin versus epirubicin in advanced breast cancer. Cancer treatment reports. ,vol. 70, pp. 261- 266 ,(1986)
M Bontenbal, , M Andersson, J Wildiers, G Cocconi, J Jassem, R Paridaens, N Rotmensz, R Sylvester, HT Mouridsen, JGM Klijn, AT van Oosterom, Doxorubicin vs epirubicin, report of a second-line randomized phase II/III study in advanced breast cancer British Journal of Cancer. ,vol. 77, pp. 2257- 2263 ,(1998) , 10.1038/BJC.1998.375
M.A Nooij, J.C.J.M de Haes, L.V.A.M Beex, J Wildiers, J Klijn, D Becquart, J Jassem, E Engelsman, L Duchateau, Continuing chemotherapy or not after the induction treatment in advanced breast cancer patients. clinical outcomes and oncologists' preferences. European Journal of Cancer. ,vol. 39, pp. 614- 621 ,(2003) , 10.1016/S0959-8049(02)00869-9
Paul Geels, Elizabeth Eisenhauer, Andrea Bezjak, Benny Zee, Andrew Day, Palliative Effect of Chemotherapy: Objective Tumor Response Is Associated With Symptom Improvement in Patients With Metastatic Breast Cancer Journal of Clinical Oncology. ,vol. 18, pp. 2395- 2405 ,(2000) , 10.1200/JCO.2000.18.12.2395
J.-M. Nabholtz, H. J. Senn, W. R. Bezwoda, D. Melnychuk, L. Deschênes, J. Douma, T. A. Vandenberg, B. Rapoport, R. Rosso, V. Trillet-Lenoir, J. Drbal, A. Molino, J.W.R. Nortier, D. J. Richel, T. Nagykalnai, P. Siedlecki, N. Wilking, J. Y. Genot, P.S.G.J. Hupperets, F. Pannuti, D. Skarlos, E. M. Tomiak, M. Murawsky, M. Alakl, A. Riva, M. Aapro, Prospective Randomized Trial of Docetaxel Versus Mitomycin Plus Vinblastine in Patients With Metastatic Breast Cancer Progressing Despite Previous Anthracycline-Containing Chemotherapy Journal of Clinical Oncology. ,vol. 17, pp. 1413- 1424 ,(1999) , 10.1200/JCO.1999.17.5.1413
K K Jain, E S Casper, N L Geller, T B Hakes, R J Kaufman, V Currie, W Schwartz, C Cassidy, G R Petroni, C W Young, A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer. Journal of Clinical Oncology. ,vol. 3, pp. 818- 826 ,(1985) , 10.1200/JCO.1985.3.6.818
A D Seidman, A Tiersten, C Hudis, M Gollub, S Barrett, T J Yao, J Lepore, T Gilewski, V Currie, J Crown, Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer. Journal of Clinical Oncology. ,vol. 13, pp. 2575- 2581 ,(1995) , 10.1200/JCO.1995.13.10.2575
S Jones, E Winer, C Vogel, L Laufman, L Hutchins, M O'Rourke, B Lembersky, D Budman, J Bigley, J Hohneker, Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer. Journal of Clinical Oncology. ,vol. 13, pp. 2567- 2574 ,(1995) , 10.1200/JCO.1995.13.10.2567
Mary E. Costanza, Raymond B. Weiss, I. Craig Henderson, Larry Norton, Donald A. Berry, Constance Cirrincione, Eric Winer, William C. Wood, Emil Frei III, O. Ross McIntyre, Richard L. Schilsky, Safety and Efficacy of Using a Single Agent or a Phase II Agent Before Instituting Standard Combination Chemotherapy in Previously Untreated Metastatic Breast Cancer Patients: Report of a Randomized Study—Cancer and Leukemia Group B 8642 Journal of Clinical Oncology. ,vol. 17, pp. 1397- 1406 ,(1999) , 10.1200/JCO.1999.17.5.1397